BACKGROUND: Despite considerable public health burden, uterine fibroid population-based incidence estimates are few. Secular trends over time are even more limited. OBJECTIVE: We sought to evaluate the incidence, 10-year secular trends, and prevalence of uterine fibroid diagnoses and describe the proportion of symptomatic women. STUDY DESIGN: We performed a retrospective population-based cohort study of women, aged 18e65 years, enrolled 2005 through 2014 in Kaiser Permanente Washington. Uterine fibroid diagnoses identified by International Classification of Diseases, Ninth Revision codes and potential covariates were extracted from computerized databases. Women with prior hysterectomy and, for incidence estimates, women with prior fibroid diagnoses were excluded. Linear trends in incidence rates over the 10-year study period were evaluated using Poisson regression models. Rates and trend tests were examined for all women, by age groups, and by race/ethnicity. RESULTS: Associated International Classification of Diseases, Ninth Revision symptom-related codes were observed in 90% of incident cases. Incidence rates for fibroid diagnoses were highest for the age group 45e49 years, 240.3 per 10,000 woman-years in 2014, and for black women across all years. Overall age-adjusted estimated incidence rates declined during the 10-year study interval, from 139.4 per 10,000 woman-years in 2005 to 101.4 in 2014 (P value trend .0008). Overall prevalence in 2014 was 9.6%, and was highest among women aged 50e54 years (15.9%). Black women had higher prevalence (18.5%) than other racial/ethnic groups. CONCLUSION: We found a decreasing trend of new uterine fibroid diagnoses among predominantly symptomatic women ages 18e65 years in a recent 10-year interval. This finding was due, perhaps in part, to secular trends of decreasing hysterectomies. Nonetheless, uterine fibroids remain a common health burden, with a prevalence of nearly 10%. Rates are disproportionately high and occur at younger ages for black women, and possibly for other non-white racial/ethnic groups. These findings are of concern, as current available long-term medical therapies remain limited.
Introduction
Uterine fibroids (uterine leiomyomata) are the most common benign neoplasm of the uterus. 1 Fibroids occur almost exclusively among reproductive-age women, increasing with age until menopause, 2 after which time they are often no longer detectable by ultrasound imaging. The main consistently identified risk factors include age, black race, nulliparity, time since last birth, and premenopausal status. Although benign, symptomatic fibroids are associated with considerable morbidity including abnormal bleeding that can lead to anemia, transfusions, or emergency surgery; pain or pressure on pelvic and abdominal organs; bladder pressure; and adverse reproductive outcomes. 8 Hysterectomy continues to be the sole definitive cure for symptomatic women, and fibroids are by far the leading indication for hysterectomy. 3, 9 Over one third of hysterectomies in the United States are for uterine fibroids. 10 Current available pharmacological agents may have side effects and a risk of relapse after discontinuation. Symptomatic uterine fibroids may affect up to 25% of all women and up to 30e40% of women in the perimenopausal age range.
14 However, as many fibroids are asymptomatic, prevalence estimates vary depending on case ascertainment methods. 14e18 Despite their considerable public health burden, associated costs of care, and impacts on the lives of many women, 13 reliable incidence estimates are still relatively few. 2, 9 Population-based estimates and evaluations of secular trends over time are even more limited. To address this gap, we conducted a retrospective cohort study to estimate the US incidence and trends over a 10-year period (2005 through 2014) , and the 2014 prevalence of uterine fibroid diagnoses in a population-based cohort of women. Secondary aims were to describe the proportion of incident cases with International Classification of Diseases, Ninth Revision (ICD-9) symptom-related codes, incidence rates, trends, and prevalence by age as well as by race/ ethnicity.
Materials and Methods

Study setting and cohort
The study setting, Kaiser Permanente (KP) Washington (KPWA), is a mixedmodel health insurance and care delivery system based in Seattle, WA. KPWA provides comprehensive care on a prepaid basis to approximately 650,000 individuals in 22 Washington counties. It contracts with the KP physicians group to provide care within an integrated group practice division (GPD) for The KPWA population generally reflects the underlying community it serves with respect to age, race, and gender. As of July 2015, the plan membership was 76% white, 10% Asian, 5% black, 1% American Indian/Alaska Native, 1% Native Hawaiian or other Pacific Islander, 3% other, and 4% unknown. Hispanic ethnicity was 5%. In 2015, the Washington State population was 81% white, 8% Asian, 4% black, 2% American Indian/Alaskan Native, and 0.7% Native Hawaiian or other Pacific Islander, as well as 13% Hispanic (5% reported 2 race/ethnicity categories).
We conducted a population-based retrospective cohort study of women enrollees for the most recent 10-year interval with complete data (Jan. 1, 2005, through Dec. 31, 2014). The cohort consisted of all women aged 18e65 years in 2005 through 2014 enrolled at KPWA for a minimum of 3 years with no previous record of hysterectomy and with at least 1 encounter within the health plan in the 3 years before entering the cohort. All study methods received approval from KPWA Human Subjects Institutional Review Board.
Data collection
We utilized KPWA electronic health care data sources, including the electronic health record (EHR). A notable feature of KPWA is the depth and longevity of its multiple computerized databases, extensively used for patient care and research for nearly 50 years. Information on enrollment, demographics, health care utilization, height and weight, diagnoses, procedures, pharmacy dispensing, and radiology and laboratory results have been maintained in automated databases since 1977. A fully integrated EHR system that documents all patient care and contacts, including clinic notes as well as telephone and email communications in KPWA-owned clinics began in 2005. All automated data sources, including the EHR, are linked using the member's unique health record number.
Race/ethnicity data were not complete in all years and for women who were not enrolled in the GPD. We thus examined race/ethnicity just in GPD enrollees. To obtain more complete race/ethnicity data on women GPD enrollees, we augmented race/ethnicity data from the EHR with data extracted via natural language processing. 19 The natural language processing search of the clinical notes reduced the unknown race/ ethnicity group from 19e13% over the 10-year study period.
Identification of uterine fibroid cases and potentially associated symptoms
Within the larger cohort of women enrollees described above, we identified uterine fibroid cases by selecting all women with the following ICD-9 diagnosis codes: 218, uterine leiomyoma; 218.0, submucous leiomyoma of uterus; 218.1, intramural leiomyoma of uterus; 218.2, subserous leiomyoma of uterus; and 218.9, leiomyoma of uterus, unspecified. For analyses of potential incident cases, women could have no fibroid diagnosis in the 3 years prior to entering the study cohort. To assess the current burden of disease, we estimated the fibroid prevalence for the final year of the cohort, 2014, without applying the 3-year exclusion.
Additional ICD-9 codes for potentially associated symptoms included: 626. 2 
Statistical analyses
Women contributed person-time from the date when they became eligible for the study through the earliest date of: disenrollment from KPWA, their 66th birthday, date of hysterectomy (if occurred after entering study cohort), or the study end date of Dec. 31, 2014. Among women with an incident uterine fibroid diagnosis, the proportion with symptom-related ICD-9 diagnosis codes AJOG at a Glance Why was this study conducted?
We conducted a population-based cohort study of women ages 18e65 years to assess the incidence, prevalence, and temporal trends of women with diagnostic codes for uterine fibroids (2005 through 2014).
Key findings
International Classification of Diseases, Ninth Revision symptom-related codes were observed in 90% of incident cases. Incidence rates were highest for women ages 45e49 years (240.3 per 10,000 woman-years), and for black women across all years. Overall age-adjusted incidence rates declined during the 10-year period. Overall prevalence (2014) was 9.6%, and was highest among women aged 50e54 years (15.9%). Black women had higher prevalence (18.5%) than other racial/ ethnic groups.
What does this add to what is known?
To our knowledge, trends in fibroid diagnoses by age/ethnicity were not previously available. Our study is unique for its size with >1 million women-years. Uterine fibroids remain a common health burden despite ongoing efforts to develop long-term medical therapies.
Original Research GYNECOLOGY ajog.org was calculated. Linear trends in annual fibroid incidence rates over the 10-year study period in 2005 through 2014 were evaluated using Poisson regression models. Rates and trend tests were examined for all women, and for each age group (18e34, 35e39, 40e44, 45e49, 50e54, and 55e65 years) in subgroup analyses. Overall annual incidence rates were age-adjusted using direct standardization to the 2014 study population.
We also examined annual fibroid incidence rates and trends by race/ ethnicity: Hispanic, non-Hispanic groups: black, white, Asian/Hawaiian/ Pacific Islander, Native American, and unknown race/ethnicity. Since race/ ethnicity data are more complete for enrollees in the GPD, we limited the race/ethnicity-specific analyses to women enrollees in GPD only. Annual incidence rates were calculated for all women in each race/ethnicity group and were age-adjusted using direct standardization to the 2014 race/ethnicityspecific study cohort. Incidence rate ratios for black women vs other race/ ethnicity groups were calculated to quantify rate differences between groups.
We estimated the overall and age-and race/ethnicity-specific prevalence of fibroids for the most recent year of the study (2014 
Results
A total of 277,821 women without a fibroid diagnosis history in the past 3 years contributed 1,040,368 womanyears during the 10-year study period. Of these, 13,803 women received a first diagnosis of uterine fibroids and were considered incident cases. Mean age for case women was 44.8 years and was 40.4 years for noncase women (Table 1) . ICD-9 codes consistent with potential uterine fibroid symptoms (eg, menorrhagia, abnormal uterine bleeding) were noted in 90% of cases. Women with fibroid diagnoses were more likely to be non-white than women without fibroid diagnoses (28.8% vs 24.7%). Among women who received fibroid diagnoses, the great majority, >80%, were classified as "unspecified" (218.9) and most diagnoses (44.4%) were assigned in outpatient clinics.
Estimated incidence rates were highest for 45e to 49-year-old women in nearly all study years and ranged from a high of 310.9/10,000 person-years in 2006 to (Figure 1) . In examining the rates by age category, the significant decline in rates over time was seen for all age groups 40 years, the groups with the highest incidence of uterine fibroid diagnoses. Among GPD enrollees, annual ageadjusted rates were the highest for black women across all years (Figure 2 ). The incidence rates for black women ranged from 196.2e286.4 per 10,000 woman-years. The incidence rate ratio for black women compared to white women was 1.7e2.6 over the 10-year period, and was 1.2e2.4 when compared to Hispanic, Asian, and Native American groups. Rates for Hispanic, Asian, and Native American womenealthough sparseewere somewhat higher than for white women during most years. There was a significant decline of the age-adjusted rates over the 10-year study period among white, Hispanic, and Asian (P value for trend <.05) but not among black and Native American women.
An examination of age and race together showed age-related patterns that were generally similar across race/ ethnicity categories, with increases up through age 49 years and subsequent steady declines through age 65 years (data not shown). Rates for black women were notably higher across all age groups, rising earlier and steadily diverging from other race/ethnicity groups through age 44 years. At that age, rates were 3-fold higher than those of white women. P for trend ¼ P value to evaluate linear trend of uterine fibroid incidence rates over time.
a Annual uterine fibroid incidence rates among all women were age-adjusted by direct standardization to 2014 study population.
Yu et al. Uterine fibroid incidence, trends, and prevalence. Am J Obstet Gynecol 2018. The observed decline in incidence rates over time prompted us to examine the data in more detail. Because fibroid diagnoses are definitively made with surgery (ie, hysterectomy), we assessed the type of visit (inpatient, radiology, outpatient, emergency department, urgent care, other) at index date over time. Our assessment showed that inpatient status at index date declined over time, while radiology visit at index date increased. In addition, we noted a decreasing percentage of women had a hysterectomy within the same year as their index date, from 91% in 2005 to 54% in 2014.
In our assessment of fibroid prevalence (Table 3) , a total of 13,142 women enrolled in 2014 had uterine fibroid diagnoses. They composed 9.6% of the 136,317 women who contributed person-time in 2014. The proportion of women with fibroids was highest (15.9%) in the age group 50e54 years, with slightly lower (13.4%) prevalence among women in the age groups on either side. In evaluating prevalence by race/ethnicity, prevalence was by far the highest for black women (18.5%) relative to all other groups and was lowest for white women (10.3%). In evaluating just the 94,522 women enrolled in the GPD in 2014, who were seen only in KPWA-owned medical centers, the prevalence was slightly higher than that of the larger cohort that included all women insured by KPWA but who could be seen at other contracted KPWA facilities (10.8% vs 9.6%).
Comment
We estimated the incidence, prevalence, and 10-year secular trends (2005 through 2014) in uterine fibroid diagnoses in a large community-dwelling cohort of women. Approximately 90% of index cases had diagnostic codes that are associated with fibroid symptoms. Based on automated indices, we observed the highest estimated incidence rates among women aged 45e49 years, although new diagnoses remained high through age 54 years. Rates were 2-to 3-fold higher for black women. As with incident diagnoses, prevalence diagnoses were highest in the older age groups (highest in women aged 50e54 years) and among black women. There was a trend of decreasing uterine fibroid diagnosis rates during the study period.
As has been observed in multiple studies of uterine fibroids, 3,5,20,21 our rates of diagnosis were the highest for women in their later reproductive/early postmenopausal years (185e311/10,000 woman-years), and fell after age 55 years. Our higher rates for black women also accord with previous reports. 3, 5, 20, 21 As all enrollees in this health plan have similar coverage, this notable difference in rates in this subgroup is not likely to reflect differences in access to care.
Uterine fibroids are often asymptomatic, and available rate estimates vary markedly by case definition, with studies based on hysterectomy-confirmed fibroid case groups reporting the lowest rates, approximately 20/10,0000 woman-years, 5, 21 and reports that include incidentally identified, universally screened cases, or cases identified from all sources, reporting higher rates of 92e128/10,000 woman-years. 5,20e23 Our rates, ranging from 101e140/ 10,000 woman-years, likely reflect predominantly symptomatic women presenting for clinical care and identified by ajog.org GYNECOLOGY Original Research a mixture of diagnostic sources (pathology, imaging, and clinical examination). Record-based data such as these are likely to represent the portion of the disease spectrum that imposes the greatest burden on women, the health care system, and society. 2, 5, 24 The incidence rates from this population-based cohort are similar to other studies focused on symptomatic/ clinically identified cases. In a recordbased study of military women, for example, the rate for the 40-year age group over a 10-year period (2001 through 2010) was 262.8/10,000 woman-years. 21 A second study, conducted with the Health Improvement Network database in the United Kingdom, reported a substantially lower incidence of 50.4/10,000 woman-years for their 45-to 49-year age group over a similar 10-year period (2000 through 2009). 25 The study methods were similar to the current study, but United Kingdom Health Improvement Network data are based on Read codes rather than ICD-9 codes, making comparisons less straightforward.
Most studies of uterine fibroid rates do not include women age >55 years. The current study included women with potentially incident fibroid diagnoses up through age 65 years; the 55-to 65-year age group comprised close to 13% of our fibroid case group. The incidence rates for this group, although the second-lowest in the cohort, were still substantially above the rates for women aged 18e34 years. A review of a random sample of 617 medical records from this cohort noted lower, but still high, confirmation rates for women 55 years (90%) vs younger case women (96%). Among confirmed cases, the proportion of older women with symptoms such as bleeding, pain, or pressure was similar to younger case women (lower for bleeding, but higher for pain).
Data on secular trends for uterine fibroid occurrence are sparse, particularly for the recent time periods. Fibroid rates increased over time in a study of military women, in which the oldest age category was "40þ" years, 21 likely a younger population than ours. The rate increases were highest for the early years, while for the 6 years of overlap with the current study (2005 through 2010), trends were similarly flat for both studies. The decline in rates noted in our report was most evident in the last 4 years (2011 through 2014) with significant declines for all age groups >39 years. The decline in incident diagnoses may be due, in part, to changes in the diagnostic sources through time: the proportion of cases diagnosed by an imaging procedure increased and the proportion of cases diagnosed by pathology decreased in the later years of our study (2011 through 2014). We found a decrease in the percentage of hysterectomies through time, as have others. 10, 26 Another explanation for the declining temporal trends in fibroid diagnoses among women age >50 years could be diminished use of postmenopausal hormone therapy associated with symptomatic uterine fibroids. 6 In addition, newer guidelines recommending initial treatment for menorrhagia as medical management 27, 28 could have affected diagnostic trends; the levonorgestrel intrauterine device was Food and Drug Administration approved for menorrhagia treatment in October 2009. 29 If initial empiric medical treatment of menorrhagia was successful, this may have resulted in fewer women being assigned a fibroid diagnostic code in the later study years, and lower hysterectomy rates. This hypothesis is highly plausible in a cost-efficient organization that does not recommend imaging studies unless the proposed test would alter treatment plans.
A potential limitation of our study is that record-based data may misclassify cases. To assess the potential for misclassification, we conducted a standardized EHR review of a random sample of 617 case women diagnosed from 2012 through 2014. The positive predictive value of the code-based diagnoses was 94% for the presence of fibroids and 78% for incident fibroids (80% for case women <55 years of age). An EHR review of 70 charts from women with no fibroid diagnosis codes, but with symptoms such as heavy uterine bleeding, found that only 4 had incident fibroid diagnoses. Uterine fibroid diagnostic codes do not fully capture "disease rates" of all women with uterine fibroids. Rather, ICD-9 codes are a surrogate marker for disease. It is possible that prevalence cases were included in our numerator when performing incidence calculations and hysterectomized women were included in our denominators. Thus, the estimated rates of new diagnoses may include some error, but are similar to those from other largedatabase cohort studies, 5, 20, 21, 23, 28 and prevalence estimates could have been spuriously low.
The strength of the current study is its population-based estimates for a large community-dwelling cohort of women, including recent trends for younger and older ages and for multiple racial/ethnic groups. To our knowledge, trends in fibroid diagnoses by age/ethnicity were not previously available. 30 Administrative data such as these are now widely available providing opportunities for detailed epidemiologic, clinical, and surveillance studies. For example, KPWA is a member of the Health Care Systems Research Network, a nationwide consortium that can share programming and data elements across 20 health care systems that cover approximately 14 million enrollees. 19 In conclusion, in our defined population of >277,000 women contributing >1 million years of person-time, we found that fibroids remain a common health event even in a generally healthy population, with a health burden in 2014 of about 10% of women enrollees between ages 18e65 years and nearly 16% of women ages 50e54 years. Incident cases had diagnostic codes suggestive of associated symptoms in 90% of women. We observed a trend of decreasing uterine fibroid incidence over the 10-year study period (2005 through 2014), overall and in nearly all age categories. Rates continue to be disproportionately high and to occur at younger ages for black women and possibly for other racial/ethnic groups, while long-term medical therapeutic options remain limited. 11, 30, 31 Data that are widely available in many US health care systems have the potential for further evaluation of the public health burden of this condition, for real-world assessment of interventions and therapies, and for improved monitoring of changes over time.
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